| Name | Title | Contact Details |
|---|---|---|
Geoff Nichol |
CMO and SVP, Global Clinical Development | Profile |
Jennifer Bzura-Lanzafame |
Senior Director, Center of Operational Excellence - World Wide R&D | Profile |
Mantej Chhina |
Head, Global R&D and Regulatory Policy | Profile |
Kendra Bolt |
Chief of Staff to the President of Worldwide Research & Development | Profile |
Kevin Eggan |
Head of Research and Early Development | Profile |
Alamar Biosciences is a biotechnology company that has developed a next generation proteomic platform with ultra high sensitivity and multiplexing capability for plasma protein detection and liquid biopsies.
ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal disease and conditions.
Checkerspot is a design-centric materials company enabling ultra-high performance consumer products.
BD Biosciences is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Virobay is focused on the development and commercialization of novel drugs through the utilization of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases, for a variety of conditions, including neuropathic pain, autoimmune diseases and fibrosis. The foundation of Virobay's proprietary cathepsin platform and the Virobay management team were spun-out from Celera Genomics, which was then a leader in cathepsin research. Virobay's clinical pipeline currently includes product candidates in neuropathic pain, dermatology, autoimmune disease and fibrosis.